Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 526

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 526
---
 is not meant to be relied upon as an exhaustive list or a detailed description of the provisions discussed and is qualified in its entirety by reference to the laws of Israel, the U.S. and Switzerland, Kadimastem’s articles of association and memorandum of association, and NLS’s (after the Merger, the combined company’s) Articles. You are also urged to carefully read the relevant provisions of the Swiss Code of Obligations and the Israeli Companies Law for a more complete understanding of the differences between being a shareholder of Kadimastem and a shareholder of NLS. Copies of the documents referred to in this summary may be obtained as described under the section entitled “ Where You Can Find More Information.” The discussion in this section does not include a description of rights or obligations under the U.S. federal securities laws or Nasdaq listing requirements. Summary of Material Differences Between the Rights of Kadimastem Shareholders and NL Shareholders

| Rights of Kadimastem shareholders                                                                                      |     | Rights of NLS Pharmaceutics shareholders                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Share Capital                                                                                                          |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| The authorized share capital of Kadimastem consists of 15,000,000 (fifteen million) ordinary shares with no par value. |     | The share capital of NLS as of the date of this proxy statement/prospectus amounts to CHF 184,738.14 divided into 4,908,034 fully paid-in registered shares (NLS Common Shares) and 1,249,904 fully paid-in registered shares (NLS Preferred Shares), each with a par value of CHF 0.03 and a participation capital (non-voting capital) of CHF 18,193.56, divided into 606,452 fully paid-in participation certificates (preferred participation certificates), with a par value of CHF 0.03 each. 
 The share capital of NLS after the Merger shall amount to CHF 228,473.94, divided into 3,745,402 fully paid-in registered shares (Common Shares), and 62,497 fully paid-in registered shares (Preferred Shares), each with a par value of at least CHF 0.06 and a participation capital (non-voting capital) of CHF 1,819.44, divided into 30,324 fully paid-in participation certificates (Preferred Participation Certificates), with a par value of at least CHF 0.06 each.                      |

288